Amylyx Pharmaceuticals Inc.
Rating
Updated: Aug 24, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative co...
Latest News
6 days ago · seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago · fool.com
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This WeekAnalysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.
1 month ago · gurufocus.com
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common StockAmylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (âAmylyxâ or the âCompanyâ) today announced the pricing of an upsized underwritten public offering of 14,090
1 month ago · zacks.com
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study WinAmylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.
1 month ago · fool.com
Why Amylyx Pharmaceuticals Stock Skyrocketed TodayAmylyx is developing a GLP-1 treatment for people with chronic low blood sugar. The experimental therapy displayed a favorable safety profile in a clinical study.
1 month ago · businesswire.com
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common StockCAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are bein.
1 month ago · seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia TranscriptAmylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia Transcript
1 month ago · marketbeat.com
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55%Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus placebo in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
1 month ago · benzinga.com
Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger LevelAmylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stock is trading higher on Tuesday after the company released highly favorable topline data from its Phase 3 LUCIDITY clinical trial.
1 month ago · reuters.com
Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trialAmylyx Pharmaceuticals said on Tuesday its experimental drug met its main goal in a late-stage trial for post-bariatric hypoglycemia, a condition marked by dangerously low blood sugar levels following weight-loss surgery.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AMLX